269 related articles for article (PubMed ID: 12668871)
1. Hyperprolactinemia in men: clinical and biochemical features and response to treatment.
De Rosa M; Zarrilli S; Di Sarno A; Milano N; Gaccione M; Boggia B; Lombardi G; Colao A
Endocrine; 2003; 20(1-2):75-82. PubMed ID: 12668871
[TBL] [Abstract][Full Text] [Related]
2. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia.
Colao A; Sarno AD; Cappabianca P; Briganti F; Pivonello R; Somma CD; Faggiano A; Biondi B; Lombardi G
Eur J Endocrinol; 2003 Mar; 148(3):325-31. PubMed ID: 12611613
[TBL] [Abstract][Full Text] [Related]
3. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
De Rosa M; Ciccarelli A; Zarrilli S; Guerra E; Gaccione M; Di Sarno A; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
[TBL] [Abstract][Full Text] [Related]
4. [Hyperprolactinemia unrelated to prolactinoma].
Krysiak R; Okopień B
Wiad Lek; 2014; 67(2 Pt 1):101-11. PubMed ID: 25764785
[TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia and prolactinoma.
Romijn JA
Handb Clin Neurol; 2014; 124():185-95. PubMed ID: 25248588
[TBL] [Abstract][Full Text] [Related]
6. Gonadotropin-releasing hormone pulsatile administration restores luteinizing hormone pulsatility and normal testosterone levels in males with hyperprolactinemia.
Bouchard P; Lagoguey M; Brailly S; Schaison G
J Clin Endocrinol Metab; 1985 Feb; 60(2):258-62. PubMed ID: 3917455
[TBL] [Abstract][Full Text] [Related]
7. Prolactinomas.
Glezer A; Bronstein MD
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):71-8. PubMed ID: 25732643
[TBL] [Abstract][Full Text] [Related]
8. Long-Term Follow-Up of Primary Medical Versus Surgical Treatment of Prolactinomas in Men: Effects on Hyperprolactinemia, Hypogonadism, and Bone Health.
Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
World Neurosurg; 2017 Jan; 97():595-602. PubMed ID: 27773859
[TBL] [Abstract][Full Text] [Related]
9. Hyperprolactinemia and prolactinomas.
Mancini T; Casanueva FF; Giustina A
Endocrinol Metab Clin North Am; 2008 Mar; 37(1):67-99, viii. PubMed ID: 18226731
[TBL] [Abstract][Full Text] [Related]
10. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
11. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
12. Hyperprolactinemia in children: clinical features and long-term results.
Catli G; Abaci A; Altincik A; Demir K; Can S; Buyukgebiz A; Bober E
J Pediatr Endocrinol Metab; 2012; 25(11-12):1123-8. PubMed ID: 23329759
[TBL] [Abstract][Full Text] [Related]
13. Hypothalamic-pituitary function in diverse hyperprolactinemic states.
Boyar RM; Kapen S; Finkelstein JW; Perlow M; Sassin JF; Fukushima DK; Weitzman ED; Hellman L
J Clin Invest; 1974 Jun; 53(6):1588-98. PubMed ID: 4208470
[TBL] [Abstract][Full Text] [Related]
14. Hyperprolactinemia and infertility.
Shibli-Rahhal A; Schlechte J
Endocrinol Metab Clin North Am; 2011 Dec; 40(4):837-46. PubMed ID: 22108283
[TBL] [Abstract][Full Text] [Related]
15. [Prolactinoma in the male. Physiopathological, clinical, and therapeutic features].
Coppola A; Cuomo MA
Minerva Endocrinol; 1998 Mar; 23(1):7-16. PubMed ID: 9691632
[TBL] [Abstract][Full Text] [Related]
16. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
17. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
18. Current treatment issues in female hyperprolactinaemia.
Crosignani PG
Eur J Obstet Gynecol Reprod Biol; 2006 Apr; 125(2):152-64. PubMed ID: 16288952
[TBL] [Abstract][Full Text] [Related]
19. Successful gonadotrophin treatment of hypogonadism in postoperative patients with macroprolactinoma and persistent hyperprolactinaemia.
Isurugi K; Kajiwara T; Hosaka Y; Minowada S
Int J Androl; 1993 Oct; 16(5):306-10. PubMed ID: 8276523
[TBL] [Abstract][Full Text] [Related]
20. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
